

PROVIDER QUICK POINTS

PROVIDER INFORMATION



March 11, 2020

Update: Medical Drug Update for Golodirsén (Vyondys 53)

On January 8, 2020, Provider Quick Point QP8-20 communicated the addition of golodirsén (Vyondys 53) to the Medical Drug Evaluation Process List under Blue Cross and Blue Shield of Minnesota (Blue Cross) medical policy II-174. Effective May 4, 2020, there will be a drug-specific Blue Cross medical policy for golodirsén (Vyondys 53) (policy II-232). The drug will be removed from medical policy II-174 and the Medical Drug Evaluation Process List and addressed under medical policy II-232 for Golodirsén.

Products Impacted

Subscribers with coverage through commercial health plans (excluding Federal Employee Program (FEP) which has separate requirements).

Reminder Regarding Medical Policy Updates & Changes:

Medical Policy changes are communicated in the Upcoming Medical Policy Notifications section of the Blue Cross Medical and Behavioral Health Policy website. The Upcoming Policies section lists new, revised, or inactivated policies approved by the Blue Cross Medical and Behavioral Health Policy Committee and are effective at minimum 45 days from the date they were posted. To access the website:

- Go to providers.bluecrossmn.com
- Under Tools & Resources, select “Medical Policy”, and read/accept the Blue Cross Medical Policy Statement
- Select the “+” (plus) sign next to “Medical and Behavioral Health Policies” to see the Upcoming Medical Policy Notifications section

Questions?

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.